lentiCRISPR v2-dCas9 Citations (10)
Originally described in: CRISPR/Cas9-based editing of a sensitive transcriptional regulatory element to achieve cell type-specific knockdown of the NEMO scaffold protein.Babaei M, Liu Y, Wuerzberger-Davis SM, McCaslin EZ, DiRusso CJ, Yeo AT, Kagermazova L, Miyamoto S, Gilmore TD PLoS One. 2019 Sep 25;14(9):e0222588. doi: 10.1371/journal.pone.0222588. eCollection 2019. PubMed Journal
Articles Citing lentiCRISPR v2-dCas9
| Articles |
|---|
| Trinucleotide Repeat-Targeting dCas9 as a Therapeutic Strategy for Fuchs' Endothelial Corneal Dystrophy. Rong Z, Gong X, Hulleman JD, Corey DR, Mootha VV. Transl Vis Sci Technol. 2020 Aug 31;9(9):47. doi: 10.1167/tvst.9.9.47. eCollection 2020 Aug. PubMed |
| C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. Ozawa T, Kaneko S, Szulzewsky F, Qiao Z, Takadera M, Narita Y, Kondo T, Holland EC, Hamamoto R, Ichimura K. Acta Neuropathol Commun. 2021 Mar 8;9(1):36. doi: 10.1186/s40478-021-01135-4. PubMed |
| RSK1 SUMOylation is required for KSHV lytic replication. Liu Z, Liu C, Wang X, Li W, Zhou J, Dong P, Xiao MZX, Wang C, Zhang Y, Fu J, Zhu F, Liang Q. PLoS Pathog. 2021 Dec 6;17(12):e1010123. doi: 10.1371/journal.ppat.1010123. eCollection 2021 Dec. PubMed |
CRISPR activation and interference screens decode stimulation responses in primary human T cells.
Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Bueno R, Nguyen VQ, Blaeschke F, Ye CJ, Marson A.
Science. 2022 Feb 4;375(6580):eabj4008. doi: 10.1126/science.abj4008. Epub 2022 Feb 4.
PubMed
Associated Plasmids |
| FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway. Zhang Y, Wang Y, Zhao G, Tanner EJ, Adli M, Matei D. J Clin Invest. 2022 May 16;132(10). pii: 151591. doi: 10.1172/JCI151591. PubMed |
| DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300. Kim HJ, Moon SJ, Hong S, Won HH, Kim JH. Nucleic Acids Res. 2022 Aug 12;50(14):7873-7888. doi: 10.1093/nar/gkac585. PubMed |
| Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Ding D, Zheng R, Tian Y, Jimenez R, Hou X, Weroha SJ, Wang L, Shi L, Huang H. Nat Commun. 2022 Oct 23;13(1):6311. doi: 10.1038/s41467-022-34024-y. PubMed |
| Integrative dissection of gene regulatory elements at base resolution. Chen Z, Javed N, Moore M, Wu J, Sun G, Vinyard M, Collins A, Pinello L, Najm FJ, Bernstein BE. Cell Genom. 2023 Apr 28;3(6):100318. doi: 10.1016/j.xgen.2023.100318. eCollection 2023 Jun 14. PubMed |
| CRISPR/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells. Kazimierska M, Podralska M, Zurawek M, Wozniak T, Kasprzyk ME, Sura W, Losiewski W, Ziolkowska-Suchanek I, Kluiver J, van den Berg A, Rozwadowska N, Dzikiewicz-Krawczyk A. Mol Oncol. 2023 Nov;17(11):2295-2313. doi: 10.1002/1878-0261.13493. Epub 2023 Aug 7. PubMed |
| Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. Ding D, Blee AM, Zhang J, Pan Y, Becker NA, Maher LJ 3rd, Jimenez R, Wang L, Huang H. Nat Commun. 2023 Aug 3;14(1):4671. doi: 10.1038/s41467-023-40352-4. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.